A cellular model for drug interactions on hematopoiesis: The use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis

Cell Biology and Toxicology

Volumn 12, Issue 1, 1996, Pages 39-53

  Leglise M C ^a   DeTailly, P Darodes ^a,b   Vignot, J L ^a,b   Le Bot, M A ^a   Le Roux, A M ^a   Riche, C ^a  

^a CHU MORVAN   (France)

^b Military Teaching Hospital Clermont Tonnerre   (France)

Author keywords

cytotoxicity; human umbilical cord blood (HCB); in vitro model; myelosuppression; normal hematopoiesis

Indexed keywords

ACETYLSALICYLIC ACID; CEFAZOLIN; CEFEPIME; CEPHALOSPORIN; CYTARABINE; DOXORUBICIN; FLUOROURACIL; VALPROIC ACID; ZIDOVUDINE;

ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; MODEL; PRIORITY JOURNAL; STEM CELL; UMBILICAL CORD;

EID: 0029996217     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00143393     Document Type: Article

References (63)

1. Abboud M, Fushen Xu, Lavia M, Laver J. Study of early hematopoietic precursors in human cord. Blood Cells. 1992;17:287-95.
2. Ardiet C, Bastian G, Favre R et al. (eds) Guide pratique de pharmacocinétique clinique en oncologie. Paris: Frison Roche Ed; 1989.
3. Aroch M, Dedenon A, Damais C, Averlant G, Guillosson JJ. Mise en évidence d'un effet protecteur de l'interleukine-1 vis à vis de la toxicité hématologique de l'azidothymidine (AZT) CR Seances Soc Biol Fil. 1992;186:206-14.
4. Barberi-Heyob M, Merlin JL, Weber B. Dosage of the anabolites of 5-fluorouracil in patients presenting with advanced breast cancer. Proc Annu Meet Am Assoc Cancer Res. 1993;33:A3187.
5. Bechmann RA, McFall PJ, Sikic BI, Smith SD. Doxorubinin and the alkylatmg anthracycline 3′-deamino-3′-(3-cyano-4 morpholinyl)doxorubicin: comparative in vitro potency against leukemia and bone marrow cells. J Natl Cancer Inst. 1988;80:361-5.
6. Bender JG, Unverzagt KL, Walker DE et al. Identification and comparison of CD34 positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood. 1991;77:2591-6.
7. Broxmeyer HE, Douglas GW, Hangoc G et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitors cells. Proc Natl Acad Sci USA. 1989;86:3828-32.
8. Broxmeyer HE, Kurtzberg J, Gluckman E et al. Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. Blood Cells. 1991;17:313-29.
9. Caldwell J. Problems and opportunities in toxicity testing arising from species differences in xenobiotic metabolism. Toxicol Lett. 1992;64/65:651-9.
10. Caux C, Favre C, Saeland Sem et al. Sequential loss of CD34 and class II MHC antigens on purified cord blood hematopoietic progenitors cultured with 113. Blood. 1989;74:1287-94.
11. Civin CI, Strauss LC, Brovall C. Antigenic analysis of hematopoiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1 a cell. J Immunol. 1984;133:157-65.
12. Dainiak N, Worthington M, Riordan MA, Kreczko S, Goldman L. 3′-Azido-3′-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br J Haematol. 1988;69:299-304.
13. Darzynkiewicz Z, Bruno S, Delbino G et al. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992;13:795-808.
14. Deldar A, Stevens CE. Development and application of in vitro models of hematopoiesis to drug-development. Toxicol Pathol. 1993;21:231-40
15. De Lin D, Volpe DA, Grieshber CK, Murphy MJ. Effects of L-phenylalanine mustard and L-buthionine-sulfoximine on murine and human hematopoietic progenitor cells in vitro. Cancer Res. 1990;50:4038-43.
16. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modification to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth. 1986;89:271-7.
17. Der Lely N, De Witte T, Muus P, Raymakers R, Preijers F, Haanen C. Prolonged exposure to cytosine-arabinoside in the presence of hematopoietic cytokines preferentially kills leukemic versus clonogenic cells. Exp Hematol. 1991;19: 267-72.
18. Dive C, Hickman JA. Drug target interactions: only the first step in the commitment to a programmed cell death. Br J Cancer. 1991;64:192-6.
19. Fauser AA, Messner HA. Granulo-erythropoietic colony in human bone marrow, peripheral blood and cord blood. Blood. 1978;2:1243-7.
20. Gallichio VS, Hughes N. Influence of interleukin-3 on Zidovudine (AZT)-induced in vitro toxicity to human hematopoietic progenitors. Int J Cell Cloning. 1992;10:99-104.
21. Gallichio VS, Hughes NK. Influence of interleukin-3 (IL3) on the hematopoietic toxicity associated with combination antiviral drugs (Zidovudine and DDI) in vitro using retrovirus-infected bone marrow cells. Int J Immunopharmacol. 1994;16:359-66.
22. Ganser A, Greher J, Völkers B, Staszewski S, Hoelzer D. Inhibitory effect of azidothymidine, 2′,3′-dideoxyadenosine, and 2′,3′-dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and patients with AIDS. Exp Hematol. 1989;17:321-5.
23. Gluckman E, Broxmeyer HA, Averbach AD et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from an Hla-identical sibling. N Engl J Med. 1989;321:1174-8.
24. Gluckman E, Thierry D, Lesage D et al. Cord blood banking for human hematopoietic cell transplantation. Prog Clin Biol Res. 1992;377:591-9.
25. Grant S, Traylor R, Bhalla K, McCrady C, Pettit G. Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells. Leukemia. 1992;6:432-9.
26. Greenberg PL, VanKersen I, Mosny S. Cytotoxic effects of 1-b-D-arabino-furanosyl-cytosine and 6-thioguanine in vitro on granulocytic progenitor cells. Cancer Res. 1976;36:4412-7.
27. Horikoshi A, Murphy MJ. Comparative effects of chemotherapeutic drugs on human and murine hematopoietic progenitors in vitro. Chemotherapy. 1982;28:480-501.
28. Johnsson M, Caiazzo T, Molina JM, Donahue R, Groopman J. Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by antiretroviral nucleoside derivatives. Br J Haematol. 1988;70:137-41.
29. Kelton JG, Huang AT, Mold N, Logue G, Rosse WF. The use of in vitro techniques to study drug-induced pancytopenia. N Engl J Med. 1979;301:621-4.
30. Kerst JM, Slaper Cortenbach CM, von dem Borne AEGKR, Van Der Schoot CE, Van Oers RHJ. Combined measurement of growth and differentiation in suspension cultures of purified human CD34 positive cells enabled a detailed analysis of myelopoiesis. Exp Hematol. 1992;20:1188-93.
31. Kurtzberg J, Carter SG. Differential toxicity of carbovir and AZT to human bone marrow hematopoietic progenitor cells. Exp Hematol. 1990;18:1094-6.
32. Léglise MC, Darodes de Tailly P, Vignot JL, Sawicki B, Riché C. Flow cytometric analysis of proliferation, differentiation and apoptotic parameters in a model of hematopoiesis in vitro applicable to pharmaco-toxicologic studies [abstract]. Cell Biol Toxicol. 1994;10:439.
33. Lemoli RM, Gulati SC. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors. Exp Hematol. 1990;18:1008-12.
34. Lista P, Brizzi MF, Rossi M, Resegotti Clark SC, Pegoraro L. Different sensitivity of normal and leukemic progenitor cells to Ara-C and IL-3 combined treatment. Br J Haematol. 1990;76:21-6.
35. Mahmoud El Sayed Y, Sadée W. The fluoropyrimidines. In: Ames MM, Powis G, Kovach JS, eds. Pharmacokinetics of anticancer agents in humans. Amsterdam: Elsevier Science; 1983:209-30.
36. Mayani H, Dragowska W, Landsorp M. Cytokine-indiced selective expansion and maturation of erythroid versus myeloid progenitors from purified cord blood precursor cells. Blood. 1993;12:3252-8.
37. Metcalf D, MacDonald HR. Heterogeneity of in vitro colony and cluster forming cells in the mouse marrow - segregation by velocity sedimentation. J Cell Physiol. 1975;85:643-54.
38. Okunewick JP, Buffo MJ, Kociban DL. Comparative toxicity of mitoxantrone and doxorubicin on hematopoietic stem cells. Exp Hematol. 1985;13:23-30.
39. Parchment RE, Huang M, Erickson-Miller CL. Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol. 1993;21:241-50.
40. Parent-Massin DM, Sensebé L, Léglise MC et al. Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases. Drug Safety. 1993;9:463-9.
41. Patton WN, Duffull SB. Idiosyncratic drug-induced haematological abnormalities. Drug Safety. 1994;12:445-62.
42. Rajantie J, Kajosari M, Ylitalo V. Fatal pancytopenia during high-dose valproate monotherapy. Eur J Pediatr. 1992;15: 619-20.
43. Saeland S, Caux C, Favre C et al. Effects of recombinant interleukin-3 on CD34-enriched normal hematopoietic progenitors and on myeloblastic leukemia cells. Blood. 1988; 72:1680-8.
44. Safa Kaya I, Dilmen U, Tppare M, Alisenses D. Valproic acid-induced pancytopenia and Coombs test positivity [letter]. Lancet. 1991;337:1227-8.
45. Sardonini CA, Ying-Jye WU. Expansion and differentiation of human hematopoietic cells from static cultures through small-scale bioreactors. Biotechnol Prog. 1993;9:131-7.
46. Sato S, White BG, Penry JK, Dreifuss, Sackellares JC, Kupferberg H J. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology. 1982;32:157-63.
47. Scadden DT, Wang A, Zsebo KM, Groopman JE. In vitro effects of stem-cell factor or interleukin-3 on myelosuppression associated with AIDS. AIDS. 1994;8:193-6.
48. Schnabel R, Rambek B, Janssen F. Fatal intoxication with sodium valproate [letter]. Lancet. 1984;28:221-2.
49. Schlunck T, Schleyer M. The influence of culture conditions on the production of colony stimulating activity by human placenta. Exp Hematol. 1980;8:179-84.
50. Smeland EB, Funderud S, Kaiheim G et al. Isolation and characterization of human hematopoietic progenitor cells: an effective method for positive selection of CD34+ cells. Leukemia. 1992;6:845-52.
51. Sommadossi JP, Carlisle R. Toxicity of 3′-azido-3′-deoxythymidine and 9-(dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitors cells in vitro. Antimicrob Agents Chemother. 1987;31:452-4.
52. Speth PAJ, Raijmakers RAP, Boezeman JBM et al. In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells. Eur J Cancer Clin Oncol. 1988;24:667.
53. Srour EF, Brandt JE, Bridell RA, Leemhuis T, Van Besien K, Hoffman R. Human CD34 HLA-DR-bone marrow cells contain progenitors cells capable of self renewal, multilineage differentiation, and long term in vitro hematopoiesis. Blood Cells. 1991;17:287-95.
54. Sungur C, Sungur A, Akpolat T, Yasavul U, Turgan C, Caglar S. Unresponsiveness to human recombinant erythropoietin in an epileptic dialysis patient secondary to valproic acid toxicity [letter]. Ann Pharmacother. 1992;26:1156.
55. Terstappen LWMM, Buescher S, Nguyen M, Reading L. Differentiation and maturation of growth factor expanded human hematopoietic progenitors assessed by multidimensional flow cytometry. Leukemia. 1992;6:1001-10.
56. Thierry D, Hervatin F, Traineau R et al. Hematopoietic progenitors cells in cord blood. Bone Marrow Transplant. 1992;10(Suppl.1):101-5.
57. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14:213-22.
58. Tohda S, Nagata K, Suzuki T, Nara N. Comparative effects of busulfan, cytosine arabinoside and adriamycine on different maturation stages of normal human bone marrow cells. Acta Haematol. 1990;83:16-21.
59. Turner CW, Cuzins J, Hutcheson C. A modified harvest technique for cord blood hematopoietic stem cells. Bone Marrow Transplant. 1992;10:89-91.
60. Volpe DA, De Lin D, Fohl K, Campbell JP, Murphy M J. Utility of human bone-marrow obtained incidental to orthopedic surgery for hematopoietic clonal assays. Pathobiology. 1991;59:53-6.
61. Volpe DA, De Lin D, Verhoeef V, Murphy MJ. Myelotoxicity of ribafutin and 3′-azido-3′-deoxythymidine, alone and in combination to human hematopoietic progenitor cells in vitro. Pathobiology. 1993;61:77-82.
62. Wagner JE. Isolation of primitive hematopoietic stem cells. Bone Marrow Transplant. 1992;25:6-9.
63. Watts RG, Emanuel PD, Zuckerman KS, Howard TH. Valproic acid-induced cytopenias: evidence for a dose-related suppression of hematopoiesis. J Pediatr. 1990;117:495-9.